Products
Online Inquiry
BAY1125976
Cat. No.:
OB0225WX-1632
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BAY1125976 is an allosteric modulator that selectively inhibits Akt1 and Akt2 with IC50 values of 5.2 nM and 18 nM, as determined by time-resolved FRET assays.
Synonym:
1402608-02-9; BAY-1125976; 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide; Imidazo[1,2-b]pyridazine-6-carboxamide, 2-[4-(1-aminocyclobutyl)phenyl]-3-phenyl-; 2-(4-(1-aminocyclobutyl)phenyl)-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide; Imidazo(1,2-b)pyridazine-6-carboxamide, 2-(4-(1-aminocyclobutyl)phenyl)-3-phenyl-; 2-(4-(1-Aminocyclobutyl)phenyl)-3-phenylimidazo(1,2-b)pyridazine-6-carboxamide
CAS No.:
1402608-02-9
Compound CID:
70817911
Formula:
C23H21N5
Formula Weight:
383.45
Specification
Targets&IC50:
Akt3: 427 nM (IC50; at 10 μM ATP); Akt2: 18 nM (IC50; at 10 μM ATP); Akt1: 5.2 nM (IC50; at 10 μM ATP)
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BAY1125976 is applied in oncological research as a potent and selective allosteric Akt1/2 inhibitor to study the disruption of the PI3K/Akt pathway in tumors harboring specific AKT mutations.
Library Information
Target:
Akt
Receptor:
Akt
Pathways:
Cytoskeletal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-21
Plate Location:
h7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
5 mg/mL; 13.04 mM
